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Abstract 
 The development of amplification technology for abnormal forms of prion 
protein in vitro has had a great impact on the field of prion research. This novel 
technology has generated new possibilities for understanding the molecular basis of 
prions and for developing an early diagnostic test for prion diseases. This review 
provides an overview of recent progress in cell-free PrPSc amplification techniques. 
 
Cell-free conversion and PMCA 
 The main molecular event of prion diseases is the conversion of the normal 
protease-sensitive form of prion protein (PrPC or PrP-sen) into pathological 
protease-resistant prion protein (PrPSc or PrP-res). According to the protein-only 
hypothesis, the continuous conversion of PrPC to PrPSc in infected hosts is the 
mechanism of prion propagation. To further understand mechanistic details of the 
conversion, numerous attempts to develop cell-free systems have been made. “Cell-free 
conversion” was first demonstrated by Caughey and colleagues in 1994 [1]. They 
showed that largely purified PrPC can be converted to the protease-resistant form only in 
the presence of purified brain-derived PrPSc. In cell-free conversion reactions, species 
and strain specificity was observed which positively correlates with in vivo transmission 
of prions [2]. However, the yield of cell-free conversion product was very limited, 
which made it difficult to determine if the newly synthesized PrPSc was infectious.  
 In order to overcome the low efficiency of cell-free conversion, Soto and 
colleagues developed a new method that can amplify PrPSc exponentially, designated 
protein misfolding cyclic amplification (PMCA) [3]. This method consists of repeated 
cycles of incubation and sonication. During the first step, prion-infected brain 
homogenate (a source of PrPSc) is incubated with excesses of normal brain homogenate 
(a source of PrPC) to allow extension of PrPSc polymers. Subsequently, sonication is 
performed to break down large PrPSc polymers into smaller pieces to increase the 
number of seeds. Soto and colleagues also demonstrated that in vitro generation of PrPSc 
was accompanied by an increase of infectivity [4]. Although the finding greatly 
strengthened the protein-only hypothesis, it was difficult to determine whether other 
molecules present in the brain homogenate are related to infectivity.  
 In an effort to clarify essential components of prion propagation in the PMCA, 
Supattapone and colleagues showed that PrPSc amplification can be achieved using PrPC 
purified from brain tissue and polyanions, such as nucleic acids [5]. Furthermore, they 
discovered that infectivity as well as PrPSc generation could be induced spontaneously, 
even without PrPSc derived from prion-infected brain tissue [6]. These results provide 
the first evidence that infectious prions can be created by using PMCA reactions with 
noninfectious components. 
 
Application of PMCA to early diagnostic tests for prion diseases 
 Another important application of the PMCA technique is the development of 
highly sensitive detection of PrPSc, the most reliable marker for prion infections. 
Detection of PrPSc in the preclinical stage of an affected host would lead to not only 
preventing spread of prion infection but also new opportunities for treating prion 
diseases; animal experiments have demonstrated that drug therapy is much more 
effective when initiated early in the incubation period [7, 8]. Using a hamster model 
infected by 263K strain, several rounds of successive PMCA enabled the ultrasensitive 
PrPSc detection in brain, blood and urine samples [9, 10]. Hence, PMCA is one of the 
most promising approaches for early diagnosis of prion diseases. However, there are 
still many technical problems in application of PMCA to routine analysis. First, it takes 
3 weeks to achieve maximal sensitivity even using the hamster 263K strain [11]. 
Second, amplification levels in other species, including mice [12], cervids [13] and 
humans [14], have been much less than those in hamster to date. Third, PMCA requires 
the use of PrPC derived from the same species brain tissues, which are often difficult to 
collect on a suitable scale. 
 
PrPSc amplification technique using recombinant PrP 
. Since the use of recombinant PrP (rPrP) as the amplification substrate could 
resolve some of the above problems, we sought to develop a new amplification method 
using recombinant hamster PrP (rHaPrP) and scrapie (263K strain) brain homogenate as 
a seed. It was necessary to find conditions under which rHaPrP could easily convert 
from protease-sensitive from (rPrP-sen) to protease-resistant form (rPrP-res), because 
rPrP was not an efficient substrate for conventional PMCA. We discovered that the 
conversion was greatly enhanced in the presence of low concentration (0.05-0.1%) of 
SDS and periodic sonication can amplify rPrP-res generation in an exponential manner 
similar to conventional PMCA using brain-derived PrPC [15] (Fig. 1). We named this 
method rPrP-PMCA. Although spontaneous formation of rPrP-res (termed rPrP-res(spon)) 
was detected after many cycles of rPrP-PMCA, PrPSc–seeded rPrP-res (termed 
rPrP-res(Sc)) and rPrP-res(spon) differed in their susceptibility to proteinase K (PK) 
digestion (Fig. 2A), thereby allowing clear and consistent discrimination between them. 
Furthermore, Fourier transform infrared spectroscopy (FTIR) analysis provided further 
evidence that they differ in conformation (Fig. 2B). Interestingly, when we examined 
the effects of dual seeding of rPrP-PMCA reactions with both rPrP-res(spon) and 
rPrP-res(Sc) using various seed ratios, competition between the two types of seeds was 
observed. This result indicates that the two fibrils are mutually exclusive and compete 
for rPrP-sen as a substrate, raising the possibility of molecular basis for in vivo 
competition/interference between prion strains.  
 The minimum amount of PrPSc detectable by rPrP-PMCA was around ~50 ag 
(5 ☓  10-17 g), or ~1,000 molecules, and it took only 2 days (2 rounds of rPrP-PMCA) 
to reach this detection limit [15]. This rapid amplification is probably due to the higher 
concentration of rPrP-sen relative to that of PrPC in brain homogenates and is a great 
advantage of rPrP-PMCA, when compared with conventional PMCA. Moreover, this 
assay could discriminate between scrapie-infected and normal hamsters using cerebral 
spinal fluid (CSF).  
 However, we observed that the efficiency of amplification, especially in low 
seed amount, was influenced by tube position, tube construction, probe age, and bath 
volume of cuphorn type sonicator. This is most likely due to varied delivery of 
vibrational energy to the samples. Although most of these variations could be overcome 
with sufficient experience and equipment, we developed a new PrPSc amplification 
assay without sonication to circumvent such problems associated with the PMCA and 
rPrP-PMCA methods. This assay, designated QUIC (quaking-induced conversion), uses 
rPrP-sen as a substrate and intermittent automated tube shaking which can be performed 
more easily than sonication [16] (Fig 1). The sensitivity and the amplification speed in 
QUIC were equivalent to those in rPrP-PMCA, and QUIC reactions also discriminated 
between normal and scrapie-infected hamster CSF samples as did rPrP-PMCA. Another 
merit is that the emergence of rPrP-res(spon) in QUIC was much later than that in 
rPrP-PMCA. These characteristics of QUIC can reduce the risk of false-positive 
reactions and makes it possible to use easier and faster detection methods, such as 
thioflavin T (ThT) fluorescence dye that can be used to monitor amyloid formation. 
Others have shown that rPrP denatured by guanidine hydrochloride can form amyloid 
fibrils when seeded with partially purified PrPSc under continuous shaking, and the 
amyloid formation can be detected using ThT fluorescence [17]. However, none of 
these assays have, thus far, been reported to achieve ultrasensitive PrPSc detection in 
readily accessible human specimens, such as CSF and blood from patients with human 
prion diseases.  
 In conclusion, striking progress has been made in cell-free PrPSc amplification 
technique, but further studies are needed to establish a practical test for an early and 
specific diagnosis of prion diseases. Additionally, these amplification technologies will 
facilitate future studies of the molecular basis of prion diseases, including the structure, 
toxic mechanism, and generation process of prions. 
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Figure legend 
Fig.1 Model of rPrP-PMCA or QUIC. In contrast to brain-derived PrPC, partial 
unfolding of rPrP-sen is essential for efficient conversion to rPrP-res. The reason for 
this remains to be determined. Sonication or shaking causes fragmentation of rPrP-res 
aggregates. These cycles can be repeated for a desired number. 
 
Fig.2  Comparisons between brain-derived PrPSc-seeded rPrP-res (rPrP-res(Sc)) and 
unseeded rPrP-res (rPrP-res(spon)). (This figure was modified from reference [15]). (A) 
PrPSc-seeded and unseeded products of rPrP-PMCA reactions were digested with PK 
and analyzed by immunoblot with R20 anti-PrP antibody. (B) FTIR spectroscopy of 
rPrP-res(Sc)
 
and rPrP-res(spon). The spectrum of the rHaPrP-sen substrate is shown for 
comparison. Overlaid spectra are from independent preparations. As expected, 
rHaPrP-sen had an absorbance maximum at ~1652 cm-1, consistent with prominent 





displayed prominent bands at lower wavenumbers (1615-1628 cm-1), 
indicating higher proportions of β-sheet. However, the location of the bands differed 
between the two types of rHaPrP-res. The rPrP-res(Sc)
 
had maxima at 1628 and 1615 
cm-1, whereas rPrP-res(spon) peaked at 1625 cm-1. These spectral differences could be due 
to differences in conformation, PK-resistant polypeptide chain length, or both. Precise 
assignments of these bands are uncertain, but the 1664 cm-1 band is often associated 
with turns, and the 1659 and 1647 cm-1
 
bands with loops or helices, and disordered 
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